Human liver glycogen phosphorylase (hlGP), a key enzyme in glycogen metabolism, is a valid pharmaceutical target for the development of new anti-hyperglycaemic agents for type 2 diabetes.
Introduction
Type 2 Diabetes mellitus (T2D) is one of the most common and serious metabolic disorders. The number of patients with T2D keeps rising and even exceeds the predictions. It was estimated that in 2015, 415 million of people lived with diabetes all around the world, while approximately 193 million were undiagnosed. This number may increase to 642 million in 2040 according to the International Diabetes Federation (IDF). IDF estimated that diabetes was the primary cause of death to almost 5 million people in 2015 [2] . The pharmaceutical recommendations for T2D thus far, include drugs as metformin (a biguanide drug), aiming at optimizing insulin-mediated glucose uptake from the cells and, therefore, leading to lower blood glucose levels [3] . However, in T2D patients a significant β-cell insulin secretory dysfunction and decreased β-cell mass due to increased apoptosis, are observed. As a result, the body can't handle increases in metabolic load [4] and oral medication shows often limited or even insufficient results. Furthermore, some of these treatments may have side effects, like hypoglycaemia, which affects the quality of diabetic patients' life. Therefore, the identification of new compounds that could result in a better management of blood glucose levels is in need. Hepatic enzymes involved in glycogen metabolism are promising targets for T2D treatment and glycogen phosphorylase (GP; EC 2.4.1.1) inhibitors (GPi's) are confirmed to be able to lead to a better hepatic glycogen balance and blood glucose levels control [5] . These results are supported by in vitro, ex vivo and in vivo studies [6] [7] [8] [9] [10] [11] [12] [13] . Furthermore, although GPi's exert their action in the liver, they have also been found to induce UCP2 (a mitochondrial inner membrane protein that uncouples mitochondrial proton gradient from ATP production) expression to protect from mitochondrial hydroxyl radicals produced by excess glucose flux [13] . This has also been observed in the muscle [14, 15] . Recently, Nagy et al, suggested that GPi's can also target pancreatic cells and hence they can improve β-cell function and survival [16] .
GP is a key enzyme involved in glycogen metabolism by catalyzing the first step of glycogen breakdown towards glucose-1-phosphate (Glc-1-P). GP has at least seven binding sites: the catalytic, allosteric, inhibitor, quercetin, new allosteric, benzamidazole and the glycogen storage binding site [11] , as shown in Figure 1 . GP follows the Monod-Wyman-Changeux model of allosteric enzymes and exists in two forms, GPb with low activity and affinity for the substrate (T-state) and
GPa with high activity and affinity for the substrate (R-state). The equilibrium between T and R state lies on a flexible loop (280s, residues 282-286) and is controlled by small molecules (metabolite effectors) that bind on the aforementioned binding sites of the enzyme. The T state is inactive and the substrate cannot reach the catalytic site since it is blocked by the 280s loop. During the allosteric transition from T to R state, the 280s loop is displaced and the catalytic site becomes accessible. The biologically active GP is a homodimer and exists in three isoforms, liver (lGP), brain (bGP) and muscle (mGP), depending on the tissue they are expressed. These isoenzymes share approximately 80-83 % sequence homology, with no insertions or deletions, and there are no structural differences at the catalytic sites of lGP and mGP.
In the past years structure-based inhibitor design studies have led to the discovery of new inhibitors with high affinity for specific GP binding sites. Most studies focused on the active site using glucose derivatives [1, 9, 11] . Recently C-β-D-glucopyranosyl imidazoles [17] and 1,2,4-triazoles [18] have been studied for their potency against the pharmacologically relevant isoform, human liver GP (hlGP), revealing the best known glucose derived inhibitors thus far, with K i values in the low nM range [17] . The efficiency of these glucose derivatives as GPi's has been attributed to the exploitation of an extensive network of polar and non-polar interactions with residues that form the βpocket within the catalytic site, so called because only the β-anomeric substituents of D-glucose can bind there. This cavity extends by the catalytic site and inhibitors binding at this site can form an extensive network of interactions with Asp283, Phe285, and Phe286 on one side and Asp339, His341, and Arg292 on the other side [19] . Our recent discovery [18] showed that 3-(C-β-Dglucopyranosyl)-5-phenyl-1,2,4-triazole's (K i =156 nM) and 3-(C-β-D-glucopyranosyl)-5-(4methylphenyl)-1,2,4-triazole's (K i =278 nM) significant potency was attributed to their extensive van der Waals interactions within the β-pocket. Herein we probe this pocket's characteristics by studying the effect on the inhibitory potency of six groups (-COO -, -CF 3 , -NO 2 ,-OCH 3 , -OH and -NH 2 ), different in size and polarity, in the para position of the phenyl group. Moreover, we have determined and analyzed the X-ray crystal structures of their GP-complexes to elucidate their protein binding pattern. We also present a new efficient protocol for the production of sufficient amounts of recombinant human liver GP, which are essential for inhibitor binding studies.
Materials and Methods
The investigated compounds were synthesized and chemically characterized as described previously [20] .
Protein production and purification
Rabbit muscle GPb (rmGPb) was purified from rabbit skeletal muscle following the protocol developed by Fischer & Krebs [21] with a slight modification (L-cysteine was replaced with 2mercaptoethanol) [22] . The optimized gene sequence encoding human liver glycogen phosphorylase (hlGPa, optimized by Eurofins Genomics, Ebersberg, Germany) was cloned on a pET-M11 vector. The N-terminus site was followed by a His-tag (6xHis) and a TEV protease prescission site.
The E. coli BL21-GOLD (DE3) strain was the host strain for the heterologous protein expression. Large cultures were produced by inoculating 1 L of LB broth (plus 20 μg/mL kanamycin, 100 mg/L pyridoxine, and 600 mg/L MnCl 2 ) with 10 mL overnight cultures (growth in the same conditions).
Cultures were grown until reaching OD 600 : 0.5-0.6, at 37 o C, 210 rpm and then protein expression was induced using 0.5 mM IPTG. Cultures were incubated for a further 16 hours at 18 o C, 210 rpm. 
Kinetic studies
GP's catalytic activity is reversible in vitro, with ratio of [Glc-1-P]/[Pi] to 0.22. In vivo the enzyme catalyzes only the degradation of glycogen since Pi concentration is much higher than Glc-1-P's. In vitro, GP can perform the reverse reaction in presence of higher concentrations of Glc-1-P, where the enzyme adds glucose residues on glycogen with direct release of Pi which is measured spectrophotometrically using the method Shaheki et al. [23] . Kinetic studies were performed at 30 °C in the direction of glycogen synthesis. 3 µg/ml rmGPb, rmGPa, or 1 μg/mL hlGPa were assayed in a 30 mM imidazole/HCl buffer (pH 6.8) containing 60 mM KCl, 0.6 mM EDTA, and 0.6 mM dithiothreitol using constant concentrations of glycogen (0.2% w/v), AMP (1 mM; only for the rmGPb experiments), and various concentrations of Glc-1-P and inhibitors. Enzyme and glycogen were preincubated for 15 min at 30 °C before initiating the reaction with Glc-l-P. Initial velocities were calculated from the pseudo-first order rate constants using five time-intervals. For the calculation and statistical evaluation of the kinetic parameters, the non-linear regression program Grafit [24] was used.
X-ray crystallography
rmGPb-inhibitor complexes were formed by diffusion of 10 mM solution of the inhibitors in the crystallization media supplemented with DMSO (15 %, v/v) in preformed rmGPb crystals at room temperature for 3 hours prior to data collection. Tetragonal T state rmGPb crystals were grown as described previously [25] . These crystals belong to space group P4 3 2 1 2 with unit cell dimensions a=b=128.5 Å and c=116.2 Å. X-ray diffraction data were collected using synchrotron radiation on station ID911-2 (λ=1.0403Å) at MAX-Lab Synchrotron Radiation Source in Lund, Sweden at room temperature on a MAR CCD detector 165 mm. To avoid crystal radiation damage the crystal was translated five times. Crystal orientation, integration of reflections, inter-frame scaling, partial reflection summation, and data reduction was performed by the program Mosflm [26] . Scaling and merging of intensities were performed by Aimless [27] and the optimum resolution was selected based on the CC 1/2 criterion [28] . Crystallographic refinement of the complexes was performed by maximum-likelihood methods using REFMAC [29] . The starting model employed for the refine-ment of the complexes was the structure of the native T state rmGPb complex determined at 1.9 Å resolution (Leonidas et al., unpublished results). Ligand molecule coordinates and topologies were constructed using JLigand [30] and they were fitted to the electron density maps by adjusting of their torsion angles. Alternate cycles of manual rebuilding with the molecular graphic program COOT [31] and refinement with REFMAC improved the quality of the models. A summary of the data processing and refinement statistics for the inhibitor complex structures is given in Table 1 and the validity of the refinement procedure was checked using the PDB_REDO server [32] . As there were more than 5 reflections per atom available, both an isotropic and an anisotropic B-factor model were considered, and the isotropic B-factor model was selected based on the Hamilton R ratio test. A TLS model for grouped atom movement with one TLS group was used. The stereochemistry of the protein residues was validated by MolProbity [33] . Hydrogen bonds and van der Waals interactions were calculated with the program CONTACT as implemented in CCP4 [34] applying a distance cut off 4.1 Å (details are provided in Table 3 ) and 4.0 Å, respectively. Figures were prepared with CCP4 Molecular Graphics [35] . The coordinates of the new structures have been deposited with the RCSB Protein Data Bank (http://www.rcsb.org/pdb) with codes presented in Table 1 . 
Results and Discussion

Kinetic studies
In order to evaluate the inhibitory potency of our six different compounds we determined their inhibitor constants (K i ) against hlGPa with kinetic experiments as described above. Kinetic experiments were also performed against rmGPa for comparison reasons (liver and muscle) and with rmGPb to validate the structural data (see below). Results are summarized in Table 2 , together with three other similar derivatives [18] . All of the compounds displayed competitive inhibition with respect to the substrate Glc-1-P as revealed by the Lineweaver-Burk plots that intersect at the same point on the y-axis for hlGPa and rmGPa. The K i values, derived from the 1/v vs [I] plots, do not display any significant differences between rmGPb, rmGPa and hlGPa as found earlier [17, 18] .
The most potent compound is CK900 with a K i value at 0.427 μM and a -NH 2 substituent. All substituents seem to have a significant impact on the inhibitory potency of hlGPa and their K i values follow the pattern -COO -> CF 3 > -NO 2 > -OCH 3 > -OH > -NH 2 . From this classification it seems that the most influential characteristic of the substituents to the inhibitory potency is their size rather than their polarity, the presence of hydrogen bond donors/acceptors, or the presence/absence of acid/base properties. This notion is further supported by previous results [18] whereas 2d, with -CH 3 group displays a K i value at 0.283 μΜ (Table 2 ). However, comparing the K i value of 2d, with that of KS172 it seems that increasing hydrophilicity by replacing hydrogens with fluorine leads to a drop in the inhibitory potency by 195 times. Furthermore it seems that all compounds show similar potency against all three enzymes and do not display a preference for any of them. The anchor point for each of the inhibitors at the catalytic site appears to be the glucose moiety which is engaged in hydrogen bond (Table 3 ) and van der Waals interactions almost identical to those that have been observed for α-D-glucose and other glucose-based inhibitors in previous studies [9, 17, 18, [37] [38] [39] . Furthermore, three conserved water molecules mediate hydrogen bond interactions between the glucopyranose moiety of each ligand and residues Asn284, Asp283, Ala673, Lys574, Thr671, Gly675, Thr676, and the phosphate group of the cofactor PLP. The triazole linker participates in a hydrogen bond interaction with the main chain oxygen of His377 (Table 3 ; Figure 4 ). Similar interactions have been previously observed with other glucose derivatives studied as GPIs [17, 18, [40] [41] [42] [43] and the increased inhibitory potency of these compounds was ascribed to the hydrogen-bond forming capacity of the heterocyclic nitrogen atoms to the main chain oxygen of His377. In addition, the triazole linker of all inhibitors participates in water mediated hydrogen bond interactions with the side chain atoms of Asp283 and the main atoms of Leu136 ( Figure 4 ). In total, KS252, KS172, CK898, JLH270, SzB102v, and CK900 engage in 82, 79, 78, 76, 75, and 84 van der Waals interactions with protein residues at the active site of rmGPb, respectively. The phenyl group is involved in an extensive network of van der Waals interactions with protein residues Glu88, Asn282, Asn284, Phe285 and His341. In addition all six inhibitors are involved in πcation interactions between their phenyl ring and the imidazole ring of His341. These interactions have been also observed with inhibitors 2a and 2d and were the source of the significant potency displayed by these compounds [18] .
Focusing on the interactions of the para substituent reveals the structural basis of their significant differences in inhibitory potency. Thus, in KS252 (K i =637.4 μM) this group (-COO -) does not form any hydrogen bond interactions with protein residues in the active site (Table 3 ) and is only involved in 7 van der Waals interactions. The carboxylate of KS252 is also at a salt bridge distance from Arg292 and His341 side chains (4.3 and 4.4 Å, respectively). In KS172 (K i =53.3 μM) the CF 3 group forms four halogen bonds with Asn282, Phe285 and Arg292 and is involved in 11 van der Waals interactions (Table 4 ). Halogen bond interactions have led to significant increment of the inhibitory potency of glycogen phosphorylase inhibitors in previous studies [44, 45] . The -NO 2 group of CK898 (K i =32.7 μM) is involved in a hydrogen bond with Arg292 and 8 van der Waals interactions. The -OCH 3 group of JLH270 (K i =5.25 μM) is not involved in any hydrogen bond interactions and forms 5 van der Waals interactions with Glu88, Asn282, Ph285 and Arg292 (Table 4 ).
Finally, the hydroxyl group of SzB102v (K i =3.66 μM) and the -NH 2 group of CK900 (K i =0.427 μM) are not involved in any direct hydrogen bond interaction with protein residues and each one participates in only three van der Waals interactions with Asn282, Ph285 and Arg292 (Table 4 ). It seems that there is no direct relation between the number of contacts and the K i values, but there is some relation between the type of contacts (i.e. hydrogen bonds, van der Waals) and the strength of binding. Thus, the proximity and the interactions of polar atoms from protein residues and water molecules to C12 of KS252 and KS172 (Table 4 ) may provide an unfavorable determinant in the binding so that the K i of these inhibitors are the worse among the six inhibitors studied. These inter-actions are not compensated by the interactions of O13 and O14 in KS252 with positive polar atoms (Arg292-NH2 and His341-NE2) since they also interact with negative polar atoms (Asn282-O and Phe285-O). The halogen bond interactions of KS172 (Table 3 ) significantly compensate for these unfavorable interactions and hence the K i of KS172 is almost 8 times lower than that of KS252. For CK898 the interactions of the NO 2 group are with polar atoms ( Table 4 ). The NO 2 group is also close to the carbonyl oxygen of the main chain of Asn282 (2.8 Å) a rather unfavorable interaction which influences negatively the K i value of this inhibitor, which is only 1.6 times lower than that of KS172. Both JLH270 and SzB102v are almost equipotent and share the same interactions with protein residues. These interactions are mostly polar-nonpolar for JLH270 and polar-polar for
SzB102v. There are not any polarity issues here and hence their K i values are 6.2 and 8.9 times lower than that of CK898, respectively. However, the close proximity of two water molecules to C13 of JLH270 may provide an unfavorable interaction influencing negatively its inhibitory potency. These water molecules within the active site are firmly bound and conserved and hence are an integral part of the structure. Finally, CK900 is the most potent inhibitor of all six studied here since it seems that has only favorable polar-polar van der Waals interactions and an additional hydrogen bond interaction with the side chain of Asn284 (Table 3) leading to a K i value 8.5 times lower than that of SzB102v. CK900 is equipotent with 2a that has a methyl group instead of an amine.
Although the physicochemical nature of the two para substituents is totally different, the β-pocket is lined by both polar and nonpolar groups and this mixed character has presented opportunities for favorable interactions for both groups. Given the significant difference of the two substituent groups their equipotency was somehow unexpected suggesting that in every step of the inhibitor optimization process structural data are needed to guide it and provide the rational for the next step.
In a previous study [46] the inhibitory potency of a series of ten N'-(β-D-glucopyranosyl)-4substituted benzoyl-ureas was assessed by kinetic and crystallographic methods. Some of these inhibitors had groups at the para position identical with the ones presented here (i.e. -H (2a), -CH 3 (2d), -OH (SzB102v), -NO 2 (CK898), -NH 2 (CK900), -OCH 3 (JLH270), and -COO -(KS252)).
Their K i values for rmGPb were at the range of low μM (i.e. 4.6, 2.3, 6.3, 3.3, 6.0, 3.2, and 85.0 μM, respectively) [46] . As it appears with the exception of the -COOgroup all other substitutions lead to almost equipotent compounds. This equipotency was not well correlated with structural data that showed significant differences in the interactions of each of the para substituents upon binding to rmGPb. Crystallographic analysis [46] showed that all these compounds induced a significant conformational change of the 280s loop compared to that of the compounds presented here (Fig. 5 ).
It seems that the energy cost for the conformational change of 280s loop dictated almost entirely the inhibitory potency and therefore the different groups at the para position of the benzyl ring did not seem to have any effect at the inhibitor's potency. In contrast, the inhibitors presented here did not cause any significant conformational change of the 280s loop (or to any other part of the protein structure) and hence the effect of the para substituent groups on the inhibitory potency is significantly more profound and better correlated with structural data. and the corresponding urea analogue [46] in black.
The best C-β-D glucopyranosyl triazole GP inhibitor reported thus far is 2b which has a 2-napthyl group ( Table 1) and displays a K i value of 0.172 μM for the liver enzyme [18] . A recent study [16] suggested that this inhibitor targets beta cells and can be repurposed as agent to preserve beta cell function or even ameliorate beta cell dysfunction in different forms of diabetes. Comparative struc-tural analysis of the rmGPb-2b and the rmGPb-CK900 reveals that the two structures are very similar. In the rmGPb-2b complex the phenyl group of 2b engages in van der Waals interactions with residues Asn282 (1), Asn284 (1), Phe285 (3), Arg292 (2), His341 (7) , and Ala383 (1). In the rmGPb-CK900 complex the para NH 2 group engages polar-polar interactions with the carbonyl oxygens of Asn282, Phe285 and the side chain of His341. Thus, although the para substituent of these two inhibitors is different in terms of polarity (hydrophobic vs hydrophilic) their interactions with protein residues lead to almost equipotent inhibition of these compounds (K i s 0.172 and 0.427 μM, respectively).
Conclusions
The effect of six different groups, in size and hydrophobicity, in 3-(C-β-D-glucopyranosyl)-5phenyl-1,2,4-triazoles has been assessed by kinetic and X-ray crystallography methods. The best compound was the one with an amine with a K i value of 430 nM for hlGPa. Structural analysis highlighted the essential components of the β-pocket within the GP active site revealing hydrophilic and hydrophobic regions which depending on the physicochemical characteristics of the inhibitor can either favor or impede inhibitor binding. However, comparison of the K i values of the six inhibitors studied and their structural mode of binding revealed that the addition of the para group led to significant increments in potency (3-4 times) only when this group exploited hydrophilic or hydrophobic interactions within the β-pocket. Finding a group that will exploit both is the next challenge in the rational design of new GPis.
